Coverage limits curb access
- GoodRx analysis cited by NPR reports roughly 12 million people lost coverage for Zepbound in the past year. - The analysis found a similar 12 million people lost coverage for Wegovy, indicating broad reimbursement rollbacks. - Reduced payer coverage, not clinical efficacy, appears to be the immediate bottleneck limiting patient access to obesity drugs. (ijpr.org)
Insurance coverage for two of the biggest obesity drugs got tighter over the past year, leaving about 12 million more people without coverage for Zepbound and another 12 million without coverage for Wegovy, according to a GoodRx analysis cited by NPR. (goodrx.com, npr.org) GoodRx said the number of people with no commercial coverage for Wegovy rose 42% in 2026 versus 2025, to more than 41 million. For Zepbound, it said more than 109 million people now lack commercial coverage after a 12% increase in noncoverage. (goodrx.com) The pullback is happening even as both drugs hold broad Food and Drug Administration approvals. Wegovy is approved for long-term weight management and, since March 2024, to cut the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity. (fda.gov) Zepbound is approved for chronic weight management and, since December 2024, for moderate to severe obstructive sleep apnea in adults with obesity. The Food and Drug Administration called that clearance the first drug treatment for that sleep disorder in this patient group. (fda.gov, fda.gov) Insurers and employers have been tightening access with exclusions, prior authorization rules, and other limits as demand stays high and the drugs’ budget impact grows. NPR reported that plans are dropping coverage outright or adding new restrictions, pushing some patients to switch medicines or pay cash. (npr.org, wskg.org) That leaves patients navigating a market where the sticker price is still high. Eli Lilly says eligible commercially insured patients can pay as little as $25 with its savings program, but its self-pay option for people whose insurance does not cover Zepbound starts at $299 for a one-month prescription. (zepbound.lilly.com) Novo Nordisk says eligible commercially insured patients can also pay as little as $25 for Wegovy through its savings offer. Its current price guide says the discount is capped at $100 a month, and eligibility restrictions apply. (novocare.com) The coverage retreat has widened the gap between patients with the same prescription but different insurance cards. NPR described people moving to lower doses, changing drugs, or stopping treatment after employers or health plans rewrote benefits for 2026. (wskg.org) For now, the main choke point is not whether the drugs work or whether regulators cleared them. It is whether a health plan will keep paying for them month after month. (goodrx.com, npr.org)
